Cardiac hypertrophy in humans can progress to cardiac failure if the underlying impetus is poorly controlled. An important direct stimulator of hypertrophy and its progression is the angiotensin II (AngII) peptide. AngII also causes hypertension that indirectly contributes to cardiac hypertrophy. Others and we have shown that estrogens acting through the estrogen receptor (ER)-␤ can inhibit AngII-induced or other forms of cardiac hypertrophy in mice. However, the proliferative effects of estrogen in breast and uterus that promote the development of malignancy preclude using the steroid to prevent cardiac disease progression. We therefore tested whether an ER␤ selective agonist, ␤-LGND2, can prevent hypertension and cardiac pathology in female mice. AngII infusion over 3 weeks significantly stimulated systolic and diastolic hypertension, cardiac hypertrophy, and cardiac fibrosis, all significantly prevented by ␤-LGND2 in wild-type but not in ER␤ genetically deleted mice. AngII stimulated the Akt kinase to phosphorylate and inhibit the glycogen synthase kinase-3␤ kinase, leading to GATA4 transcription factor activation and hypertrophic mRNA expression. As a novel mechanism, all these actions were opposed by estradiol and ␤-LGND2. Our findings provide additional understanding of the antihypertrophic effects of ER␤ and serve as an impetus to test specific receptor agonists in humans to prevent the worsening of cardiovascular disease. (Endocrinology 154: 4352-4364, 2013) E strogens have been shown to reduce arterial resistance, stimulate arterial dilation and blood flow, lower blood pressure (BP), mitigate the damage of arteries and the heart to various forms of injury, decrease vascular inflammation and atherosclerosis, and prevent cardiac hypertrophy in animals and humans (reviewed in Reference 1).
and subsequent up-regulation of genes that promote cardiac hypertrophy (4) . We previously published that 17␤-estradiol (E2) inhibits calcineurin activity through up-regulating the transcription of the modulatory calcineurininteracting protein (MCIP1) gene. This occurred from membrane ER␤ signaling through the Akt kinase, preventing cardiomyocyte hypertrophy in vitro (5) and in vivo (6) . Inhibiting dephosphorylation of NFATs by calcineurin led to the retention of the NFAT transcription factors in cytoplasm and could account for the ability of E2 to dampen the downstream effects of calcium dysregulation in female mice (2) .
In addition, the progression of cardiac hypertrophy to dilation and heart failure is portended by and partially results from interstitial myocardial fibrosis. Fibrosis interferes with coordinated excitation-contraction coupling of cardiomyocytes in systole and diastole and induces diastolic stiffness, impairing cardiac output (7) . We recently showed that E2 signaling through membrane ER␤ in cardiac fibroblasts prevents angiotensin II (AngII) or endothelin-1-induced fibrosis in vitro and in vivo (8) . This results from E2 preventing TGF-␤ production and subsequent stimulation of the conversion of fibroblasts to myofibroblasts, severely limiting collagen production that is crucial to cardiac fibrosis (8) .
Regarding human hypertrophy, studies indicate that heart failure and death postmyocardial infarction occur less frequently in women who are taking hormone replacement therapy (9) and improved survival during heart failure is associated with estrogen use (10, 11) . With aging, the incidence of hypertrophy in postmenopausal women exceeds that of age-matched men (10) but can be reversed by hormone replacement therapy (11) . Hormone replacement also lowers vascular resistance and decreases left ventricular (LV) hypertrophy in hypertensive, postmenopausal women (12) . However, E2 engaging ER␣ promotes breast and uterine proliferation that contributes to sexsteroid responsive cancers (13, 14) . Thus, selective, agonistic engagement of ER␤ might prove useful to prevent multiple events leading to cardiac hypertrophy and progression and avoid undesirable actions that stem from ER␣ activation.
In these studies, we investigated whether a novel and selective ER␤ agonist (15) could prevent AngII-induced hypertension, cardiac hypertrophy, and fibrosis as a preclinical proof of concept for testing such compounds in humans.
Materials and Methods

Animal models
All studies were approved by the Animal Care and Research and Development Committees at the Department of Veterans Affairs Medical Center (Long Beach, California). Ten-week-old, ovariectomized female C57/BJ6 mice were obtained from Harlan/Sprague Dawley and were housed in 12-hour on/off lighting and fed rodent chow devoid of soy or most plant products. Osmotic minipumps (Alzet; DURECT Corp) were filled with either AngII (0.7 mg/kg⅐d) in saline, saline alone (control), AngII plus 100 L of an ER␤ agonist, ␤-LGND2 (0.5 mg) or ␤-LGND2 alone. The minipumps were inserted sc under inhaled chlorofluorane anesthesia to provide a 21-day infusion. In some mice, an E2 pellet (0.1 mg, 21 d release pellets; Innovative Research of America) was inserted under the skin, but these mice did not receive the ER␤ agonist. This pellet is well documented to produce physiological levels of E2 in the serum of mice (6) . In all studies, five to six mice were used per experimental condition.
At inception and after 21 d, the mice were weighed. Blood pressure was measured four times during the 21-day period, using the CODA noninvasive BP measuring system (Kent Scientific). At the experimental conclusion, the hearts were removed and weighed, the LV dissected free, and the ratio of heart or LV to total body weight was determined. The heart was then processed for a variety of studies. Estrogen loss or administration did not significantly affect body weight over the 3-week period of the study, but heart weight was normalized to initial body weight. For comparison, ovariectomized female wild-type, and ER␤ gene-deleted mice were obtained from Ken Korach (National Institute of Environmental Health Sciences) and Harlan and were originally created by Smithies and colleagues (16) . These mice were subjected to the same conditions described for wildtype, ovariectomized female mice, involving administration of AngII Ϯ E2 or ER␤ agonist, and all mice were identically housed and fed the same chow at the Veterans Affairs animal research facility.
mRNA and protein expression
Total RNA was extracted using the QIAGEN RNeasy minikit following the manufacturers' protocol. All the samples were treated with deoxyribonuclease-free (Ambion). RNA purity and concentrations were measured by UV spectrophotometry (A 260 and A 280 ). cDNA was synthesized using approximately 500 ng RNA and Oligodeoxythymidine primers with the Improm-II reverse transcription system (Promega). Quantitative PCR (qPCR) was used to examine the relative expression of ␤-myosin heavy chain (MHC), inositol polyphosphate-5-phosphatase (Inpp5f), MCIP1, and GATA4, and expression was normalized using expression of the housekeeping mRNA glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers were designed using Primer3 (http://frodo.wi.mit.edu/) and were blasted to check specificity (primers: GATA4 forward, 5Ј-ggctcccagagattcttcct-3Ј, GATA4 reverse, 5Ј-ctctgctacggccagtaagg-3Ј; ␤-MHC forward, 5Ј-atagcaacagcgaggctctttctg-3Ј, ␤-MHC reverse, 5Ј-ggagctcacctaccagacaga-3Ј; Inpp5f forward, 5Ј-aacttgggaaaggcctgg-3Ј, Inpp5f reverse, 5Ј-catggagctgcggatctt-3Ј; MCIP11 forward, 5Ј-gactggagcttcattgactgcgaga-3Ј, MCIP11 reverse, 5Ј-aaggaacctacagcctcttggaaag-3Ј; GAPDH forward, 5Ј-ccacagtccatgccatca-3Ј; GAPDH reverse, 5Ј-ggatgaccttgcccacag-3Ј).
Primers were designed to have an annealing temperature of 55°C and to amplify regions of approximately 150 bp. PCR amplicons sizes were confirmed by agarose gel electrophoresis prior to quantitative RT-PCR analysis. For quantitative RT-PCR analysis, 500 ng of cDNA was used in a 50-L reaction consisting of 25 L of SYBR Green ER qPCR Supermix (Invitrogen), 1 L of 10 M forward/reverse primer stocks, and nuclease-free water. Thermocycling was carried out using the iCycler (Bio-Rad Laboratories) with a melting curve temperature of 60°C. Relative mRNA levels were calculated using the cycle threshold method.
For relative protein detection, immunoblots were carried out on protein extracted from the left ventricles of mice from all conditions, after separation by SDS-PAGE and transfer to nitrocellulose, as we described (6, 8) . Antibodies to cardiac myosin heavy chain, collagen I, MCIP1, phospho-ERK1(tyr 202) and ERK2(tyr204), and total, phospho-Ser473 and total Akt, and serine 9 phospho-glycogen synthase kinase (GSK)-3␤ and GATA4 antibodies were from Abcam and Santa Cruz Biotechnology Inc. Brain natriuretic peptide (BNP) antibodies (Penninsula Laboratories) were also used. GATA4, Inpp5F, and control small interfering RNAs (siRNAs) and a GATA4-luciferase reporter plasmid was from QIAGEN.
Fibrosis
Left ventricular tissues were fixed in 4% paraformaldehyde solution. Paraffin-embedded tissue sections (5 m) were stained with Masson's trichrome for the presence of interstitial collagen fiber accumulation that is indicative of cardiac fibrosis. The ratio of interstitial fibrosis to the total LV area was calculated from 10 randomly selected microscopic fields from each of five sections per heart using National Institutes of Health ImageJ analysis software (n ϭ 5-6 mice per condition).
Further quantification of collagen deposition was made by ventricular content of hydroxyproline, a breakdown product of collagen, determined by a modified method of Bergman and Loxley (17) . The ventricular tissues (0.5 g from each mouse) were homogenized and hydrolyzed in 6 M HCl at 110°C for 24 hours in a sealed reaction vial. The sample was dried and the residue resuspended in sterile water; 0.5 mL of chloramine T was added for 5 minutes, and then Ehrlich's reagent (3 mL) was added and the mixture left for 18 hours at room temperature. The intensity of the red coloration that developed was measured by a spectrophotometer at 558 nm.
Ligand binding assay
Ligand binding assay was performed as previously described (15 (1-3 nM) and ER LBD (␣ or ␤) using the conditions described above. Results are represented as relative binding affinity (RBA) to ER␣ or ER␤ with an RBA of E2 considered as 1. Nine binding curves were generated.
Transient transfection and reporter gene assay
Transactivation assays were performed as described earlier (15, 18) . Human ERs (ER␣ and ER␤) were cloned from prostate cDNA into a pCR3.1 vector backbone. Human embryonic kidney-293 cells were plated at 125 000 cells/well of a 24-well plate in DMEM ϩ5% charcoal-stripped fetal bovine serum. The cells were transfected using Lipofectamine (Invitrogen) with 0.25 g estrogen response element-luciferase (a gift from Dr Carolyn L. Smith, Baylor College of Medicine, Houston, Texas), 0.02 g cytomegalovirus-luciferase (renilla luciferase for correction purposes), and 12.5 ng of plasmid for expressing full-length human ER␣ or 25 ng of plasmid for human ER␤. The cells were treated 24 hours after transfection with various concentrations of ␤-LGND2 (1 pM to 10 M), and luciferase assays were performed 48 hours after transfection.
Isolation and experiments in cardiomyocytes
Neonatal rat cardiomyocytes were isolated from the hearts of 1-to 3-day-old rats or from term pregnant female rats (Charles River) using a cardiomyocyte isolation kit (Worthington), according to the manufacturer's instructions, as previously described (5) . The myocytes were incubated in DMEM/F12 supplemented with 10% fetal bovine serum, 1ϫ insulin-transferrinselenium (Sigma) antibiotic and antimycotic, and 10 g/mL fibronectin (to aid adherence). In some studies, a GATA4 luciferase DNA construct (QIAGEN) with a Renilla luciferase control was expressed in the myocytes using lipofectamine for a subsequent luciferase determination that represents transactivation activity (luciferase assay kit from Promega). Transfected cells were recovered for 24 hours and synchronized overnight in medium containing very low serum (0.1%) and then exposed to AngII with or without estrogenic compounds for 24 hours. Myocytes were then lysed with a reporter lysis buffer (Promega) and a dual luciferase assay was performed, and the promoter activity was measured using a luminometer. Values are expressed as arbitrary units using a Renilla luciferase reporter for internal normalization. Experiments were done in triplicates per condition, and the study was repeated three times.
Rat uterotrophic assay
All animal studies were performed in accordance with the current guidelines for animal welfare. The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee of the University of Tennessee Health Science Center (Memphis, Tennessee). Female Sprague Dawley rats, 200 -250 g of body weight, were randomized into groups of five animals. The animals were either sham operated or ovariectomized and were then injected with saline vehicle, 50 g/kg⅐d estradiol sc, or 10 mg/kg⅐d ␤-LGND2 (sc) for 14 days. At the end of the treatment, the animals were killed, and the uteri were weighed.
Statistics
The results are shown as bar graphs based on the calculation of mean Ϯ SEM data from five to six mice per condition except for mice treated with ␤-LGND2 or E2 alone (four mice). Significance was determined by ANOVA plus Scheffe's post hoc test and was taken at P Ͻ .05.
Results
Angiotensin-induced cardiac hypertrophy is inhibited by E2 and an ER␤ agonist
Numerous noncardiac properties of ␤-LGND2 were described in a previous publication that demonstrated the in vivo ER␤ selectivity of this compound (15) . ␤-LGND2 is a nonsteroidal selective ligand that binds to ER␤ with a relative binding affinity compared with estradiol of 1 but to ER␣ with an estradiol-compared relative affinity of 112 (15) . In our previous work, ␤-LGND2 did not affect ER-␣ selective pathways involving the hypothalamic-pituitarygonadal axis and testes weights in male mice and uterine weight in ovariectomized female mice, indicating the absence of any cross-reactivity with ER-␣ at the administered dose, 30 mg/kg⅐d daily by sc injection (15) . Here we present ligand binding assay results, indicating that although ␤-LGND2 bound to ER␤ with an affinity equipotent to that of estradiol (1.2 RBA), it bound to ER␣ 153-fold less strongly than the same concentration of estradiol used for the ER␣ binding assay (Supplemental Figure 1 , published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). Similarly, transactivation studies indicate that ␤-LGND2 activated the estrogen response element-luciferase reporter via expressed ER␤ with an EC 50 of 5.1 nM and through expressed ER␣ with an EC 50 of 119 nM, a selectivity of approximately 24-fold. Because the effect of ER ligands on the uterus is mediated by ER␣, a utertrophic assay was used to demonstrate the selectivity of ␤-LGND2 in vivo. Administration of 10 mg/kg⅐d ␤-LGND2 for 14 days did not result in noticeable increase in uterine weight compared with ovariectomized vehicle-treated animals (Supplemental Figure 2) . As expected, estradiol increased the uterine weight significantly, corroborating previous publications and validating the assay. These results confirm that administration of approximately 50-fold more ␤-LGND2 in the uterotrophic studies, compared with the total amount used in our cardiac hypertrophy and fibrosis studies (see below), did not result in ER␣ activation.
To determine the effects of ␤-LGND2 in the cardiovascular system, we used a model that is relevant for human cardiac disease by infusing AngII or saline (control) for 3 weeks into ovariectomized, female mice by implanted osmotic minipump. AngII infusion resulted in significant cardiac hypertrophy, particularly of the LV (Figure 1, A  and B) . Coadministration of E2 (by sc pellet) or the ER␤ agonist, ␤-LGND2 (infusion of 0.5 mg over 21 d), comparably and significantly inhibited approximately 65% of the AngII-induced hypertrophy in wild type (WT) mice. In contrast, neither E2 nor ␤-LGND2 inhibited AngII-induced hypertrophy in ovariectomized, ER␤ knockout (KO) mice (Figure 1, A and B) . In ER␤ KO ventricles, ER␣ protein expression was comparable with WT mouse ventricles (Supplemental Figure 3) . Neither ␤-LGND2 nor E2 administration alone to four mice each was different from saline, consistent with our previous studies for E2 (6) . Previously we determined that E2 had no protective effects against induced cardiac hypertrophy in ER␤ KO mice (6) . The current results affirm that it is ER␤ that mediates the antihypertrophic effects of E2 and establish here that ␤-LGND2 is effective in this regard as a specific ER␤ agonist (15) .
ER␤ inhibits markers of cardiac hypertrophy
Proteins and signaling mechanisms that are important to the hypertrophic process in the heart were also investigated. In the normal ventricle, MHC ␣ is dominantly expressed compared with a small amount of MHC␤ that is produced; however, this is reversed in the hypertrophic heart (19) . We found strong expression of MHC␣ and weaker expression of MHC␤ proteins in the ventricles of saline-infused, ovariectomized WT or ER␤ KO mice (n ϭ 6) ( Figure 2A ). The relative expression of the two MHC protein isoforms in both mice was reversed from 3 weeks of AngII treatment, and the AngII effect was prevented significantly by ␤-LGND2 coinfusion in WT mice. In contrast, coinfusion of ␤-LGND2 and AngII had no effect on AngII-induced expression of MHC isoforms determined from the ventricular protein of ER␤ KO mice ( Figure 2B ). Administration of ␤-LGND2 had no effects on expression of either MHC␣ or -␤ isoforms in the absence of AngII (absence of effects for E2 alone was previously shown in reference 6).
We also determined the protein expression of BNP in the ventricles of the various mice. BNP is reexpressed as a fetal gene/protein in the ventricles of the hypertrophied heart, mainly to antagonize hypertrophic stimuli, thereby preventing decompensation and progression to heart failure (20, 21) . We found that AngII and ␤-LGND2 each strongly induced BNP protein expression in WT mouse ventricles, compared with saline infusion, but only AngII accomplished this in ER␤ KO mouse ventricles ( Figure  2C ). We previously showed that E2 stimulated BNP expression in both WT and ER␣ KO mouse heart but not strongly in ER␤ KO mice (6) .
Peptides such as AngII or endothelin-1 and catecholamines signal through their respective G proteincoupled receptors to cardiac hypertrophy. In part this occurs through activating ERK (22) . AngII administration strongly induced ERK activity in the ventricles of both mouse models ( Figure 2D ), and the ER␤ agonist significantly inhibited the ERK activation by AngII but only in WT mice.
Numerous stimuli for the induction of cardiac hypertrophy activate protein phosphatase 2B (calcineurin) that is highly implicated in the pathogenesis of this heart disorder (3, 4) . An important protein that binds to and inhibits the activity of calcineurin is MCIP1 (23, 24) . Here we assessed the ability of ␤-LGND2 to regulate MCIP1 
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Pedram gene and protein expression in the LV, correlating to regulating in vivo hypertrophy. As seen in Figure 2E , MCIP mRNA ( Figure 2E , top panel) and protein ( Figure 2E , bottom panel) expressions were strongly stimulated by the ER␤ agonist in WT mice ventricles in the presence of AngII but insignificantly in ER␤KO mice hearts. Importantly, AngII had no effect itself or on MCIP1-modifing actions of ␤-LGND2 in WT mice. We previously reported that E2 by itself up-regulates MCIP1 mRNA expression in cultured cardiomyocytes, and knockdown of MCIP1 with siRNA in these cells reversed the ability of E2 to inhibit both calcineurin activity and cell hypertrophy in vitro (5). E2 also stimulated MCIP expression in the hearts of WT but not ER␤ KO mice, unaffected by coadministration of AngII to the former (6). Our data here and in conjunction with previous results (5) indicate an ER␤ agonist up-regulates MCIP1 expression in vivo as a likely mechanism to inhibit calcineurin activity and AngII-induced cardiac hypertrophy.
Novel targets of ER␤ signaling to suppress cardiomyocyte hypertrophy
Active glycogen synthase kinase, GSK3␤, suppresses cardiac hypertrophy. GSK3␤ activity is negatively modulated from phosphorylation at serine 9 by Akt, the latter activated by prohypertrophic stimuli (25) . An important target for GSK3␤ in opposing cardiac hypertrophy is the prohypertrophic transcription factor, GATA4 (26, 27) . GSK3␤ directly phosphorylates GATA4, inhibiting the ability of this transcription factor to transactivate genes associated with the hypertrophic phenotype (27) . We therefore investigated whether AngII and E2/ER␤ interact to regulate this important pathway. In cultured cardiomyocytes, AngII stimulated GSK3␤Ser9 phosphorylation that was significantly blocked by E2 or ␤-LGND2 ( Figure  3A , left panel). In vivo, AngII infusion caused a similar increase in this inactivating phosphorylation of GSK3␤ in WT and ER␤ KO mouse ventricles that was prevented by coadministration of either estrogenic compound, the latter only in WT mice ( Figure 3B, right panel) . AngII also stimulated the activating phosphorylation of Akt (ser473) both in vitro and in vivo ( Figure 3B) , and E2 or ␤-LGND2 prevented Akt activation in cardiomyocytes and the WT mice only. Linking these actions, the AngII-induced inactivating phosphorylation of GSK3␤ in cardiomyocytes was prevented by LY294002, a selective AKT inhibitor ( Figure 3C ).
As mentioned, an important downstream target of active GSK3␤ is the GATA4 transcription factor (27) . We found here that AngII stimulated both the mRNA and protein expression of this transcription factor in cardiomyocytes, prevented by coincubation with E2 or ␤-LGND2 ( Figure 3D ). Importantly, AngII also stimulated GATA4 transcriptional activity, determined from a GATA4-luciferase reporter and likely resulting from GSK3␤ inactivation in cardiomyocytes ( Figure 3E ). AngIIstimulated GATA4 activity was also inhibited by E2 and ␤-LGND2. The ␤-MHC gene is up-regulated in cardiomyocytes as an important marker of the transition to hypertrophy (5) and is a known target for GATA4 in these cells (28) . To further link this pathway, cardiomyocytes were transfected with control or GATA4 siRNA and ␤-MHC expression was determined by qPCR. The ability of AngII to stimulate ␤-MHC mRNA expression was prevented by GATA4 knockdown ( Figure 3F ). We also determined ␤-MHC expression in vivo and found that AngII stimulated this mRNA in both WT and ER␤ KO mouse ventricles, whereas E2 or ␤-LGND2 prevented this action of AngII only in WT mice ( Figure 3H , right panel).
How do E2 and ␤-LGND2 potentially inhibit Akt, resulting in increased GSK3␤ activity and the downstream effects through GATA4 that represent a novel antihypertrophic pathway for E2/ER␤ action? It is recognized that Akt activity is negatively regulated by several phosphatases, including the Inpp5F in cardiomyocytes (29, 30) . Inpp5F degrades phosphoinositide (3-5) P3, thus inactivating Akt (30) . We found here that AngII inhibited the mRNA expression and protein abundance of this phosphatase in vitro ( Figure 3G ) and in vivo ( Figure 3H ). Interestingly, E2 and ␤-LGND2 each prevented these AngII actions but did not influence phosphatase expression themselves ( Figure 3, G and H) . Thus, E2/ER␤ derepresses Inpp5f in the setting of AngII. To further implicate Inpp5f, we knocked down endogenous phosphatase expression with siRNA ( Figure 3I ) and determined Akt activating phosphorylation. AngII caused the stimulation of Akt and resulting GSK3␤ Ser9 phosphorylation comparably in control siRNA and Inpp5f siRNA conditions, although some enhancement was seen with the latter. In contrast, the ability of ␤-LGND2 to inhibit both Akt and GSK3␤ phosphorylations was significantly reversed only by Inpp5f siRNA ( Figure 3I) . Thus, by derepressing Inpp5f, ␤-LGND2 restores GSK3␤ activity. As a result, GATA4 is not activated by AngII, resulting in decreased expression of the hypertrophic marker ␤MHC mRNA that we show. These findings overall indicate a new mechanism by which ER␤ inhibits cardiac hypertrophy.
ER␤ activation inhibits AngII-induced hypertension
Angiotensin has direct effects on the myocardium (31) but also has actions on the vasculature that promote cardiac hypertrophy through increased systemic vascular resistance (32) . Angiotensin is a potent vasoconstrictor and is considered to be a key peptide in the development of arterial hypertension in humans, often serving as a primary target for antihypertensive therapies (33) . ER␤ has been implicated to prevent increased BP because ER␤ KO male and female mice develop hypertension with aging (34) . Therefore, we determined whether ␤-LGND2 modulates AngII effects on BP. In the ovariectomized, WT female mice, AngII infusion significantly stimulated increases in both systolic and diastolic arterial blood pressures, and this was substantially and comparably prevented by equimolar ␤-LGND2 or E2 (Table 1) . AngIIinduced hypertension in ER␤ KO mice was comparable with BP increases in WT mice because endogenous ER␤ in WT mice was not engaged by E2 due to ovariectomy. Importantly, attenuation of hypertension by either ␤-LGND2 or E2 in ER␤ KO mice was insignificant. Therefore, opposition to the AngII hypertensive response was significantly different in WT and ER␤ KO mice. Our results suggest that ER␤ importantly opposes both the direct and indirect effects of AngII that lead to hypertension and cardiac hypertrophy.
ER␤ agonist inhibits cardiac fibrosis
Interstitial fibrosis of the myocardium develops during the progression of cardiac hypertrophy to myocardial dilation and contributes to the resulting heart failure (35) . As a result of fibrosis, the heart stiffens and is progressively incapable of maintaining cardiac output. Impaired cardiac output can lead to a paucity of oxygenation of vital organs including the heart itself, contributing to the apoptotic death of cardiac myocytes that has been observed from this oxidative stress (36) .
We previously showed that E2, acting through membrane ER␤ in the cardiac fibroblast, substantially prevents the events that lead to AngII-induced fibrosis (8) . Here we compared the effects of ␤-LGND2 and E2 to prevent this important development in myocardial disease progression. We found that each estrogenic compound caused a 90%-95% reduction in AngII-induced fibrosis in ovariectomized, WT female mice heart ventricles ( Figure 4A ). This was also reflected as ␤-LGND2 or E2 inhibition of hydroxyproline content in the ventricles of the AngII-infused WT mice ( Figure 4B ). Hydroxyproline is a major breakdown product from metabolism of collagen that is a critical protein and feature of fibrosis. In addition, the estrogenic compounds inhibited collagen I protein content in the ventricles of these mice ( Figure 4C ), an important form of collagen found in human myocardium undergoing fibrosis (37) . In contrast, there were insignificant effects of ␤-LGND2 or E2 on AngII-induced fibrosis or hydroxyproline or ␤-LGND2 on collagen I in the ER␤ KO mice. Ventricles from WT or ER␤ KO mice infused with saline (control), administered E2 (6), or infused ␤-LGND2 in the absence of AngII (n ϭ 3 mice) showed no effects on the small amount of fibrosis seen. These results indicate that an ER␤ agonist is extremely effective in suppressing cardiac fibrosis that results from AngII action in vivo.
Figure 3 (Conitnued). cardiomyocytes is prevented by an Akt inhibitor (LY294002)
. Data are from three experiments combined, and GAPDH serves as loading control. *, P Ͻ .05 for control vs AngII; ϩ, P Ͻ .05 for AngII vs AngII ϩ LY294002. D, GATA4 mRNA (upper panel) and protein (lower panel) expression in cardiomyocytes are stimulated by AngII but inhibited by E2 or ␤-LGND2. *, P Ͻ .05 for control vs AngII; ϩ, P Ͻ .05 for AngII vs AngII plus E2 or ␤-LGND2. E, AngII activates GATA4 transcriptional activity, inhibited by estrogenic compounds. Cardiomyocytes were transfected with a GATA4-luciferase reporter construct and recovered, and luciferase activity was determined after 24 hours of incubation. The study was done three times and data were combined. *, P Ͻ .05 for control vs AngII; ϩ, P Ͻ .05 for AngII vs AngII ϩ E2 or ␤-LGND2. F, AngII-stimulated ␤-MHC mRNA in cardiomyocytes is dependent on GATA4. GAPDH is the loading control. siRNA validation is shown. Data are from three experiments; ϩ, P ϭ .05 for control vs AngII ϩ control siRNA; ϩ, P Ͻ .05 for AngII ϩ control siRNA vs AngII ϩ GATA4 siRNA. G, Inpp5f protein (left panel) and mRNA (right panel) expression are suppressed by AngII but prevented by E2 or ␤-LGND2 in cardiomyocytes. Data are from three experiments. *, P Ͻ .05 for control vs AngII; ϩ, P Ͻ .05 for AngII vs AngII ϩ E2 or ␤-LGND2. H, E2 or ␤-LGND2 derepresses the effects of AngII on Inpp5f protein (left panels) and mRNA (right panels) expression only in WT mouse ventricles. AngII also stimulates ␤-MHC mRNA expression in vivo, prevented by E2 or ␤-LGND2. *, P Ͻ .05 for control vs AngII or AngII ϩ E2 or ␤-LGND2 in ER␤ KO mice; ϩ, P Ͻ .05 for AngII vs AngII plus E2 or ␤-LGND2 in WT mice. I, Inpp5f knockdown prevents ␤-LGND2 inhibition of AngII activation of Akt and the resulting inhibitory phosphorylation of GSK3␤. Data are from three experiments. *, P Ͻ .05 for control vs AngII under either siRNA condition or AngII ϩ ␤-LGND2 ϩ control siRNA vs AngII ϩ ␤-LGND2 ϩ Inpp5f siRNA; ϩ, P Ͻ .05 for AngII vs AngII ϩ E2 or ␤-LGND2. 
Discussion
Preventing the worsening of cardiac hypertrophy and fibrosis that can ultimately progress to heart failure would have great value to intervene in this common cause of death in humans. Previous studies by multiple groups, including our own, have shown that estrogen can prevent the development of cardiac hypertrophy and fibrosis in various female mouse models and in humans. In ovariectomized mice, E2 administration prevents ventricular remodeling after myocardial infarction (38) or genetic models of cardiac hypertrophy (39). Jazbutyte et al (40) showed that administration of an ER␤-selective agonist, 8b-VE2 (Schering Pharmaceutical), to ovariectomized spontaneously hypertensive rats lowered systolic BP and attenuated hypertrophy of the left cardiac ventricle. In addition, remodeling of the right ventricle is induced by pulmonary hypertension and is prevented by estrogen acting through ER␤ (41) . Whether E2 attenuates pulmonary hypertension per se is controversial (42) . In humans, post- menopausal women taking sex steroids showed a significant decrease in LV mass, compared with such women not taking hormone replacement (43) . Hormone replacement also significantly decreases the LV mass index in hypertensive women (12, 44) . In these latter studies, the mechanisms and ER isoforms that mediate these desirable effects of estrogen were not determined. We report that a novel ER␤ agonist, ␤-LGND2, strongly inhibits the cardiac hypertrophic response to AngII infusion in WT but not ER␤ KO mice. In these studies, we found that ␤-LGND2 was comparable with E2 in preventing cardiac hypertrophy. The ER␤ agonist also impressively prevented the increased interstitial fibrosis/collagen deposition in the myocardium that is induced by AngII and eventually impairs cardiac function (7, 35) . Several laboratories have reported that AngII acting through its type I receptor induces TGF-␤1 production that results in phosphorylated mothers against decapentaplegic-2/3 phosphorylation and trafficking to the nucleus, in which these transcription factors induce the genes responsible for cardiac fibrosis (45, 46) . This may be in part related to perivascular fibrosis, resulting from altered extracellular matrix composition and from the transition of cardiac fibroblasts to myofibroblasts (45) . We previously showed E2/membrane ER␤ inhibits these events, and here we report comparable inhibition of fibrosis by ␤-LGND2.
AngII activates several pathways to produce hypertrophy, but a prominent signal for many hypertrophic stimuli is calcium signaling to the up-regulation of calcineurin (protein phosphatase 2B) activity (3, 4) . When calcineurin is induced, it dephosphorylates and promotes the translocation of the transcription factor NFATc3 to the nucleus. In the nucleus, NFATc3 cooperates with GATA4 and myocyte enhancing factor transcription factors to stimulate hypertrophic gene expression (47, 48 ). An important protein that prevents calcineurin activity is the antihypertrophic protein MCIP1. Here we report that ␤-LGND2 stimulates MCIP1 mRNA and protein expression in the ventricle. Previously we found that siRNA directed to MCIP1 substantially reversed the inhibitory effects of E2 on calcineurin activity, new protein synthesis, and hypertrophy of the cardiomyocyte. This mechanism accounted for the modulation of NFAT protein translocation to the nucleus and related transcriptional activity, stimulated by AngII and inhibited by E2 (5).
Another well-established signal by which G proteincoupled receptors including the AngII type I receptor signal to cardiomyocyte hypertrophy is through activating ERK (22) . Here we find that AngII administration over 3 weeks induces ERK activation in the ventricles of WT and ER␤ KO mouse models ( Figure 2D ). ␤-LGND2 significantly inhibited ERK activation by AngII in WT mice but failed to do so in ER␤ genetically deleted mice.
A key feature of cardiac hypertrophy is the reversal of the normal pattern of MHC isoform expression in ventricular muscle that results from the actions of hypertrophic agents. Here we found that the ER␤ agonist maintains the ratio of MHC␣/MHC␤ expression in the normal heart by reversing the effects of AngII. Furthermore, BNP expression was stimulated by ␤-LGND2 in the WT mouse hearts. Interestingly, the hypertrophic peptide, AngII, also stimulated the production of BNP expression that maintains fluid and salt homeostasis and thereby limits cardiac decompensation (21) . Genetic deletion of the guanylate cyclase A protein, the functional receptor for BNP (and atrial natriuretic peptide), results in pronounced hypertrophy in response to numerous stimuli (49) . Previously we showed that E2-induced ANP was important for the inhibition of AngII-induced ERK in cultured myocytes (5) . Based on those results, we propose that the ability of ␤-LGND2 by itself to stimulate BNP in vivo, as we show here, could limit some hypertrophic signaling by AngII.
We also investigated an important mechanism of cardiac hypertrophy involving the action of the antihypertrophic kinase, GSK3␤, and show for the first time that estrogen/ER␤ inhibits a pathway involving inactivation of this kinase, both in cardiomyocytes and in the in vivo heart. AngII caused an inactivating phosphorylation of GSK3␤ at serine 9 through Akt activation, resulting in enhanced GATA4 transcriptional activity. GATA4 is a transcription factor that has been highly implicated to contribute to the remodeling of the ventricle, underlying cardiac hypertrophy (26, 27) . Here we show that E2 and ␤-LGND2 prevent AngII-induced Akt activation and the resulting inactivating phosphorylation of GSK3␤. It is established that active GSK3␤ physically associates with, phosphorylates, and thereby down-regulates GATA 4 transcriptional activity in cardiomyocytes (27) . Therefore, estrogenic compound(s) prevention of GSK3␤ inactivation provides a mechanism by which AngII-induced GATA4 transcriptional activity is inhibited. We report that GATA4 transcriptional activity that is stimulated by AngII is inhibited by the estrogenic compounds and reduces the expression of the ␤-MHC mRNA, a target of GATA4 (28) and a marker of cardiac hypertrophy/ventricular remodeling. We further showed that the mRNA and protein for the Inpp5F phosphatase that inactivates Akt in cardiomyocytes (29) was down-regulated by AngII, but this was reversed by E2 and ␤-LGND2. Derepression of Inpp5F by ␤-LGND2 was then shown to be required for the prevention of AngII-stimulated Akt and the resulting GSK3␤ inactivating phosphorylation. Overall, ER␤ in-hibits multiple signals that underlie AngII-induced cardiac hypertrophy.
AngII administration in vivo has been reported to cause hypertension (50) , potentially inducing cardiac hypertrophy indirectly. ER␤ stimulates nitric oxide synthase activity and nitric oxide production, preventing hypertension as deduced from a mouse model of ER␤ deletion (34) . Nitric oxide is generated in the heart and in endothelial and vascular smooth muscle cells and is a well-recognized antihypertrophic factor (51) . We previously showed that E2 stimulates nitric oxide production in cardiomyocytes (5) and in several arteries in vivo, the latter involving ER␣ and ER␤ (52) . We report here that AngII infusion causes significant increases in both systolic and diastolic blood pressures that persist for the duration of the experiment in both WT and ER␤ KO mice. Importantly, E2 and the ER␤ agonist have comparably significant effects to lower BP and restore normotension only in WT but not ER␤KO mice. Thus, ␤-LGND2 has the potential to lower BP seen from AngII excess, a situation found in human hypertension (53) . This also is likely to be important for the antihypertrophic effects of the ER␤ agonist, as mentioned. Interestingly, E2-induced prevention of the hypertensive response to AngII also required ER␤ presence. This is consistent with the in vivo development of hypertension that results from the aging of ER␤ genetically deleted male and female mice (34) .
In summary, engaging ER␤ with an agonist significantly inhibits the ability of AngII to stimulate hypertension, cardiac hypertrophy, and cardiac fibrosis in vivo. In our experimental model, the relatively short duration of AngII infusion does not result in significant cardiac functional compromise (6), thus allowing us to determine whether starting estrogenic compounds early diminishes disease induction. It will be important to test in the future whether more advanced disease could be reversed by ER␤ agonists to prevent progressive cardiac pathology. Selective ER␤ agonists are particularly attractive because they lack the breast and uterine proliferative effects of E2 or selective ER modulators that act through ER␣ to promote the malignant transformation of these tissues (13, 14) . We also speculate that males might also benefit from ER␤ agonists, and we intend to test this hypothesis in additional rodent models. Positive additional data would support the testing of select ER␤ agonists in humans.
